LDL Cholesterol Lowering in The Management of Atherosclerotic Cardiovascular Disease Risk

Lipid specialists Drs. Lynne Braun and Michael Miller discuss the importance of LDL cholesterol management for prevention and management of atherosclerotic cardiovascular disease (ASCVD). The role of non-statin therapies including emerging evidence with PCSK9 inhibition on major CV outcomes is presented in this dynamic presentation.

Lipid Management
Member Cost: $0Non-member Cost: $0
Credit Hours: 1.0 CE contact hours, 0.6 pharmacology

Course Overview

Register

Reducing LDL-C with Non-Statin Therapies

Lipid specialists Drs. Lynne Braun and Michael Miller discuss the importance of LDL cholesterol management for prevention and management of atherosclerotic cardiovascular disease (ASCVD). The role of non-statin therapies including emerging evidence with PCSK9 inhibition on major CV outcomes is presented in this dynamic presentation.

Learning Objectives

Upon completion of this continuing education course, participants will be able to:

  • Describe how to interpret cholesterol guidelines and identify patient populations with unmet needs on statin therapy.
  • Explain best practices for reducing LDL-C with non-statin therapies.

Supported by an independent educational grant from Amgen, Inc.

Faculty

  • Lynne Braun, PhD, CNP, CLS, FAHA, FAAN, FPCNA
  • Michael Miller, MD, FACC, FAHA